Ciprofloxacin concentrations in human fluids and tissues following a single oral dose
- PMID: 3596861
Ciprofloxacin concentrations in human fluids and tissues following a single oral dose
Abstract
Ciprofloxacin is a new quinolone carboxylic acid derivative which exerts its antibacterial activity at very low concentrations against a wide spectrum of microorganisms. Ciprofloxacin serum and urine concentrations were studied in 10 healthy volunteers after a single 250 and 500 mg oral dose. The concentration in ascitic fluid was determined in four male patients undergoing paracentesis after a single oral 250 mg dose (two patients) and 500 mg dose (two other patients). The penetration of ciprofloxacin into the human tonsils and turbinate bones was also determined in eight patients undergoing tonsillectomy or turbinectomy 3 h after a single oral 250 mg administration. Ciprofloxacin concentrations were determined by an agar diffusion test utilizing E. coli as reference strain. Ciprofloxacin is rapidly absorbed after oral administration (Ka = 2.67 and 1.93 mcg/ml) and its serum concentration does not vary significantly with sex and dosage (Cmax = 2.61 and 1.99 mcg/ml after a single 500 mg and 250 mg oral dose). Urinary concentrations of ciprofloxacin are twice higher after a single 500 mg dose than after a 250 mg one and are still high after 24 h (37.2 and 25.3 mcg/ml). The concentrations of ciprofloxacin in ascites, tonsils and turbinate bones are several times higher than its MICs against the majority of Gram+ and Gram- aerobic bacteria. The in vitro activity of ciprofloxacin and its human pharmacology suggest a twice daily 250 of 500 mg dosing for infections caused by multiple antibiotic-resistant bacteria, and a once a day dose in the treatment of urinary tract infections.
Similar articles
-
[Antibacterial activity of ciprofloxacin in the urine during four days after a single 500 mg and 750 mg oral dose].Pathol Biol (Paris). 1994 Jun;42(6):587-92. Pathol Biol (Paris). 1994. PMID: 7854859 Clinical Trial. French.
-
Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.Am J Med. 1987 Apr 27;82(4A):97-102. Am J Med. 1987. PMID: 3578334
-
Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.Int J Antimicrob Agents. 2006 Dec;28(6):551-9. doi: 10.1016/j.ijantimicag.2006.07.026. Epub 2006 Nov 13. Int J Antimicrob Agents. 2006. PMID: 17101261 Clinical Trial.
-
Penetration of ciprofloxacin into gynecologic tissues.Am J Med. 1987 Apr 27;82(4A):133-8. Am J Med. 1987. PMID: 3555027 Review.
-
The clinical pharmacology of losartan in Japanese subjects and patients.Blood Press Suppl. 1996;2:62-6. Blood Press Suppl. 1996. PMID: 8913542 Review.
Cited by
-
The effectiveness of multivariate and univariate spectrophotometric techniques for the concurrent estimation of ornidazole and ciprofloxacin HCl in tablet formulation and spiked serum: estimating greenness and whiteness profile.BMC Chem. 2024 Jan 23;18(1):17. doi: 10.1186/s13065-024-01126-1. BMC Chem. 2024. PMID: 38263037 Free PMC article.
-
Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.Antimicrob Agents Chemother. 1989 Feb;33(2):181-4. doi: 10.1128/AAC.33.2.181. Antimicrob Agents Chemother. 1989. PMID: 2719462 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of ciprofloxacin.Clin Pharmacokinet. 1990 Dec;19(6):434-61. doi: 10.2165/00003088-199019060-00003. Clin Pharmacokinet. 1990. PMID: 2292168 Review.
-
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003. Drugs. 1988. PMID: 3292209 Review.
MeSH terms
Substances
LinkOut - more resources
Research Materials